Reference
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013). Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides, 44, 75–86. https://doi.org/10.1016/j.peptides.2013.01.014
Info
FirstAuthor:: Marathe, Chinmay S.
Author:: Rayner, Christopher K.
Author:: Jones, Karen L.
Author:: Horowitz, Michael
~
Title:: Glucagon-like peptides 1 and 2 in health and disease: A review
Year:: 2013
Citekey:: MaratheEtAl_2013_GlucagonlikePeptides1
itemType:: journalArticle
Journal:: Peptides
Volume:: 44
Pages:: 75-86
DOI:: 10.1016/j.peptides.2013.01.014
Link
Abstract
The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as ‘incretin’ hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent.
Yellow: Interesting
Image ( Page 3)
